Youn H. Kim

Youn H. Kim

Auto-generated profile, based on publicly available information

Youn H. Kim

Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
YKYoun H Kim
Youn H Kim
MBMartine Bagot
Martine Bagot
LPLauren Pinter-Brown
Lauren Pinter-Brown
ARAlain H Rook
Alain H Rook
PPPierluigi Porcu
Pierluigi Porcu
KYKentaro Yonekura
Kentaro Yonekura

15 July 2007 in Blood
Verified
Journal Article
Closed access
PDF file
YKYoun H. Kim
Youn H. Kim
RWRein Willemze
Rein Willemze
NPNicola Pimpinelli
Nicola Pimpinelli
SWSean Whittaker
Sean Whittaker
EOElise A. Olsen
Elise A. Olsen
RHRichard T. Hoppe
Richard T. Hoppe
Currently availabel staging systems for non-Hodgkin lymphomas are not useful for clinical staging classification of most primary cutaneous lymphomas. The tumor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sézary syndrome (SS) is not appropriate for other primary cutaneous lymphomas. A usable, unified staging system would improve the communication about the state of disease, selection of appropriate management, standardization of enrollment/response criteria in clinical trials, and collection/analysis of prospective survival data. Toward this goal, during the recent meetings of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC), the representatives have established a consensus proposal of a TNM classification system applicable for all primary cutaneous lymphomas other than MF and SS. Due to the clinical and pathologic heterogeneity of the cutaneous lymphomas, the currently proposed TNM system is meant to be primarily an anatomic documentation of disease extent and not to be used as a prognostic guide.

10 November 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YKYoun H. Kim
Youn H. Kim
MTMahkam Tavallaee
Mahkam Tavallaee
USUma Sundram
Uma Sundram
KSKatrin A. Salva
Katrin A. Salva
GWGary S. Wood
Gary S. Wood
SHSteven M. Horwitz
Steven M. Horwitz
Purpose: In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sézary syndrome (SS) is quite variable. Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS. Tissue and blood biomarkers of clinical response were explored. Patients and Methods: In this phase II study, patients with MF or SS with negligible to 100% CD30 expression levels were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses. The primary end point was overall global response rate. Secondary end points included correlation of tissue CD30 expression level with clinical response, time to response, duration of response, progression-free and event-free survivals, and safety. Results: Of the 32 patients enrolled and treated, 30 patients had available efficacy evaluations. Objective global response was observed in 21 (70%) of 30 patients (90% CI, 53% to 83%). CD30 expression assessed by immunohistochemistry was highly variable, with a median CD30max of 13% (range, 0% to 100%). Those with <5% CD30 expression had a lower likelihood of global response than did those with 5% or greater CD30 expression (P < .005). CD163 positive tumor-associated macrophages, many of which coexpress CD30, were abundant in tissue. Peripheral neuropathy was the most common adverse event. Conclusion: Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF or SS with a wide range of CD30 expression levels. Additional biomarker studies may help optimize rational design of combination therapies with brentuximab vedotin.

12 January 2012 in Blood
Verified
Journal Article
Open access
PDF file
YKYoun H. Kim
Youn H. Kim
DDita Gratzinger
Dita Gratzinger
CHCameron Harrison
Cameron Harrison
JBJoshua D. Brody
Joshua D. Brody
DCDebra K. Czerwinski
Debra K. Czerwinski
RLRonald Levy
Ronald Levy
We have developed and previously reported on a therapeutic vaccination strategy for indolent B-cell lymphoma that combines local radiation to enhance tumor immunogenicity with the injection into the tumor of a TLR9 agonist. As a result, antitumor CD8+ T cells are induced, and systemic tumor regression was documented. Because the vaccination occurs in situ, there is no need to manufacture a vaccine product. We have now explored this strategy in a second disease: mycosis fungoides (MF). We treated 15 patients. Clinical responses were assessed at the distant, untreated sites as a measure of systemic antitumor activity. Five clinically meaningful responses were observed. The procedure was well tolerated and adverse effects consisted mostly of mild and transient injection site or flu-like symptoms. The immunized sites showed a significant reduction of CD25+, Foxp3+ T cells that could be either MF cells or tissue regulatory T cells and a similar reduction in S100+, CD1a+ dendritic cells. There was a trend toward greater reduction of CD25+ T cells and skin dendritic cells in clinical responders versus nonresponders. Our in situ vaccination strategy is feasible also in MF and the clinical responses that occurred in a subset of patients warrant further study with modifications to augment these therapeutic effects. This study is registered at www.clinicaltrials.gov as NCT00226993.

4 August 2022 in Blood
Verified
Journal Article
Open access
PDF file
EOElise A. Olsen
Elise A. Olsen
SWSean Whittaker
Sean Whittaker
RWRein Willemze
Rein Willemze
LPLauren Pinter-Brown
Lauren Pinter-Brown
FFFrancine Foss
Francine Foss
JSJulia Scarisbrick
Julia Scarisbrick
The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.

1 July 2017 in Cancer Cell
Verified
Journal Article
Closed access
KQKun Qu
Kun Qu
LZLisa C. Zaba
Lisa C. Zaba
ASAnsuman T. Satpathy
Ansuman T. Satpathy
PGPaul G. Giresi
Paul G. Giresi
RLRui Li
Rui Li
HCHoward Y. Chang
Howard Y. Chang